ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Assessing Follow-Up Duration in Intraductal Papillary Mucinous Neoplasm Patients.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of an Algo-Based Decision-Making Tool to Compare Real-Life Clinical Practice in a Single Tertiary Center with the Kyoto IPMN Surveillance Recommendations.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND With the continuous advancement of cross-sectional imaging technology, the number of incidentally discovered intraductal papillary mucinous neoplasms (IPMN) of the pancreas has been increasing annually. More IPMN patients are suitable for regular follow-up than for surgical resection. This study aimed to explore the appropriate follow-up intervals for IPMN patients with multiple worrisome features (WFs) and high-risk stigmata (HRS). MATERIAL AND METHODS In this single-center retrospective study, IPMN patients with a follow-up period of more than 6 months up to June 2023 were included, and the intervals between the initial diagnosis and the onset of a newly developed WF/HRS were recorded. RESULTS The median time intervals between the appearance of newly developed WFs/HRS in patients without WFs/HRS and those with ≤2 WFs at initial diagnosis were significantly longer than that in patients with >2 WFs and those with HRS (30.0 months vs 21.0 months vs 7.0 months vs 10.0 months; p<0.001). Among postoperative patients, those with low-grade dysplasia were younger at initial diagnosis than those with high-grade dysplasia and invasive carcinoma (59.8 years old vs 69.4 years old; p=0.027). CONCLUSIONS Patients with cysts ≥30 mm can undergo medical examinations biannually. For IPMN patients with cysts <30 mm and containing >2 WFs or HRS, a follow-up interval of 0.5-1.0 years may be appropriate, and regular follow-up of 1.5-2 years is reliable for patients with cysts <30 mm and ≤2 WFs. Moreover, advanced age may be an important risk factor for malignant progression of IPMN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.